Hypertrophic cardiomyopathy (HCM) is a complex genetic cardiovascular disease that often remains under-recognised, with ongoing challenges in diagnosis, risk stratification, and treatment. The HCM Knowledge Track brings together expert-selected resources — from congress presentations and trial updates to imaging insights, patient perspectives, and debates on therapeutic strategies. It offers a structured view of current evidence to support your understanding of diagnosis, guide your awareness of therapeutic advances, and broaden your perspective on expert debates relevant to practice.

Supported by Bristol Myers Squibb

Lipoprotein(a) [Lp(a)] is a genetically determined lipid particle recognised as an independent driver of cardiovascular risk, even when other lipid levels are well controlled. The Lp(a) Knowledge Track curates expert-selected resources — from epidemiological studies and clinical discussions to measurement guidance, therapeutic perspectives, and expert debates. It provides clarity on Lp(a)’s role in cardiovascular risk, supporting your awareness of testing challenges and exploring strategies that may inform your future management decisions.

Supported by Novartis